Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Auscann Group Holdings Ltd ACNNF

AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.


OTCPK:ACNNF - Post by User

Post by DeanMD6on Aug 02, 2017 4:25pm
122 Views
Post# 26540089

This stock in going to be a gold mine in a few years.

This stock in going to be a gold mine in a few years.Recent Highlights - Strong progress of Australian market strategy: o Strategic partnership with Tasmanian Alkaloids o Medical cannabis cultivation licence secured o Medical Outreach Program commenced First medicinal cannabis crop harvested in Chile Strengthened skills and expertise with appointment of renowned medical cannabis expert Dr Danial Schecter as Chief Medical Advisor Successful $12 million capital raise via a placement with significant support from investors Strong industry partnership and cultivation advancements position AusCann as a leader in the burgeoning medicinal cannabis industry in Australia AusCann. - OPERATIONAL The Company continues to draw on Canopy Growth Corporations expertise in the cultivation, manufacturing and importation of products and has leveraged this across its Australian operation. Operations over the past quarter have seen South America become an attractive region for AusCann upon the completion of the first harvest in Chile. In addition to this, AusCann has seen significant operational advancements in Australia, with its strategic partnership with Tasmanian Alkaloids Pty Ltd and attainment of its medicinal cannabis licence from the Office of Drug Control.
<< Previous
Bullboard Posts
Next >>